Over a third of psoriatic arthritis patients stopped two or more biologics, but few were truly refractory

Design

Retrospective cohort from 5 Nordic biologics registries

Population

14,362 patients with psoriatic arthritis starting a first b/tsDMARD

Primary outcome

Prevalence of difficult-to-manage and treatment-refractory disease

Effect

Stopped 2 or more: 36%; difficult-to-manage 2% to 3%; treatment-refractory about 1%

Using five Nordic biologics registries, this study followed 14,362 patients with psoriatic arthritis from their first biologic or targeted synthetic DMARD (1999 to 2020; median follow-up 6.3 years) and applied components inspired by the EULAR framework for difficult-to-manage and treatment-refractory disease.

36% stopped two or more advanced therapies, 18% three or more and 10% four or more. But once symptoms and objective inflammation were required, only 2% to 3% met the difficult-to-manage definition, and about 1% were treatment-refractory. Women, depression and opioid use became more common with each additional discontinuation.

The gap between the number who cycle through drugs and the number with objective inflammation suggests that much drug switching is driven by pain and comorbidity rather than uncontrolled psoriatic arthritis.

• Before a third or fourth biologic switch, confirm objective inflammation — swollen joints, raised CRP or imaging
• Screen for depression and fibromyalgia in patients cycling through biologics
• Review opioid use, which rose with each discontinuation
• Refer for pain management alongside rheumatology when inflammation is controlled but symptoms are not

Why it matters

It reframes repeated biologic failure as a prompt to reassess, not just to switch.

Don't overread it

Registry-based components approximate the EULAR definitions; they do not validate them.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.